Black Diamond Therapeutics (BDTX) Revenue (2025)
Black Diamond Therapeutics' (BDTX) quarterly Revenue came in at $70.0 million in Q1 2025.
Black Diamond Therapeutics (BDTX) Revenue (2025) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 1 years of Revenue data on file, last reported at $70.0 million in Q1 2025.
- Quarterly Revenue changed N/A year-over-year to $70.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $70.0 million (changed N/A YoY) and the FY2025 annual result came in at $70.0 million, changed N/A from the prior year.
- Revenue held at $70.0 million in Q1 2025.
- In the past five years, Revenue ranged from a high of $70.0 million in Q1 2025 to a low of $70.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 674.14 Mn |
| 10 | Black Diamond Therapeutics | 125.35 Mn | 14.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 70.00 Mn |